Regeneron Pharmaceuticals' Inmazeb, a combination of the monoclonal antibodies atoltivimab, maftivimab and odesivimab-ebgn, become the first Ebola treatment to gain FDA approval. The agency approved a vaccine for preventing the virus in December.
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.